Management change at ALK

Udgivet den 31-07-2017  |  kl. 10:11  |  

Copenhagen, 2017-07-31 10:11 CEST (GLOBE NEWSWIRE) --  

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that Flemming Pedersen, CFO and member of the Board of Management, has decided to resign his position and leave ALK to join a privately owned Danish company in another industry. 

Chairman of the Board of Directors, Steen Riisgaard, and President & CEO, Carsten Hellmann said: We would like to offer our sincere thanks to Flemming for his strong contributions to ALK's development over the past seven years. We will miss him, but respect his decision to move on in his career. 

Flemming Pedersen said: After seven inspiring and successful years with ALK, I have decided to join another company. ALK has become the undisputed leader in allergy immunotherapy and is now pursuing numerous exciting opportunities for further growth. While I am sad to leave ALK and will miss the many outstanding colleagues, partners and investors with whom I have the pleasure to work, I am also looking forward to my new challenge. 

Flemming Pedersen will leave ALK by 31 January 2018 at the latest. A search for a new CFO will now be initiated.
 

ALK-Abelló A/S

 

For further information please contact:
Carsten Hellmann, President & CEO
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014
 

About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy - a treatment of the underlying cause of allergy. The company has approximately 2,300 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, and South-East Asia, and Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on Nasdaq Copenhagen. Find more information at www.alk.net.

 

Vedhæftede filer:

FM_19_17UK_31072017.pdf

Udgivet af: NPinvestordk

Seneste nyheder

09:17 Aktier/åbning: Zealand tager gigantisk kurshop på milliardaftale
08:54 Obligationer/åbning: Flad renteudvikling før vigtig inflationsrapport
08:46 Zealands aktiekurs kan stige mere end 30 pct. spår Jefferies
08:43 Zealand Pharma har stor tiltro til kombination mellem kronjuvel og mulig "best in class"-molekyle
08:29 Råvarer: Svagere dollar sender oliepriserne i opadgående retning
08:22 Aktier/tendens: Zealand har udsigt til topplacering i ventet grønt marked
08:17 Zealand Pharma har fundet en partner til Petrelintid: Topchef ser enormt potentiale i overskudsdeling
08:00 Tysk våbenproducent skruer lidt ned for salgsvæksten i år efter rekord i 2024
07:37 Zealand har fået gigantaftale med wauw-effekt i hus mener Nordnet
07:32 Obligationer/tendens: Nye rentestigninger i sigte med fokus på amerikansk inflation
07:22 Zealand Pharma finder schweizisk partner til sin kronjuvel
07:06 Novo får skåret kursmålet hos Jefferies efter skuffende Cagrisema-tal
06:58 EU vil indføre nye afgifter som svar på amerikansk told
06:49 DSV får købsanbefaling hos Jefferies: Ser positivt på strategi og Schenker-opkøb
06:38 Genmab får skåret kursmålet hos Morgan Stanley efter Hexabody-afgørelse
06:37 Asien: Bekymrede investorer forsøger at finde fodfæste
06:35 EU vil lægge told på varer fra USA for 26 mia. euro.
06:34 Ukraine støtter forslag om våbenhvile - USA genoptager militær støtte
06:34 Trump dropper toldfordobling - Ontario suspenderer eksporttold
06:34 Nordea får kursmålet sænket med 5 pct. hos Citi